Announcing CancerLife's Quality of Life Clinical Trial with the John Wayne Cancer Institute
Are you interested in the results of our study? Enter your email and we will add you to our private email list and contact you before the results become public:
Study # 1: CancerLife's Original Validation Study with the John Wayne Cancer Institute
CancerLife and Quality of Life specialist, Marlon Saria, PhD, are pioneering a Quality of Life Research Study focused on cancer patients, caregivers and survivors. This study is a follow-up to the validation study conducted this past summer, which proved that patients can collect their own data inside the CancerLife App. Study highlights included:
- 88% of participant users stated that CancerLife improved their Quality of Life
- 100% stated that CancerLife was easy-to use
- 5.8 Average Journal Updates/Per Week !
- 3.7 Social Shares/Per Week!
Users love CancerLife and are engaging on the platform almost everyday!
The Quality of Life Clinical Trial: Its Goal
A pioneering, real world evidence (RWE) Quality of LIfe Clinical Trial, conducted by the John Wayne Cancer Institute (A member of the Providence Health System) and CancerLife, was recently approved. The goal of the blind, randomized trial is to validate if and how CancerLife can improve patients, survivors and caregivers quality of life and become the first "complimentary digital therapeutic" in cancer care.
Additionally, the trial will provide deep insights into how social support, Patient Reported Outcome (PRO) symptom data collection and other factors can impact patient outcomes.
The study piggybacks on mounting research evidence (including prior research at Sloan Kettering) which indicates that patients' Quality of Life may improve (by up to 18%) when patients share their moods (and get social support from family, friends and fellow patients)... and, most important, share their symptom data with care teams.
The Quality of Life Clinical Trial: Defined
Participation is easy, rewarding and only takes about one minute a day, three to five days a week.
Approximately 1000 participants (caregivers, survivors and patients) will be recruited to participate in the study. Participants will use the CancerLife App for social sharing purposes and to collect PRO symptom data. Participants will take a series Quality of Life surveys, which wlll be tracked and monitored over a five-month period.
Additionally, IBM Watson AI technology will analyze social sharing data and conversations using its proprietary machine learning and natural language processing algorithms. IBM Watson will help uncover key insights into participants cancer journeys.
CancerLife's Commitment to the World
Understanding the correlation and implications on how social sharing and Patient Reported Outcome data affect patients quality of life has breakthough potential as it may help doctors better understand how the next wave of cancer drugs will impact patients' quality of life.
CancerLife is deeply committed to help patients, survivors and caregivers–around the world–experience a better quality of life. With that said, CancerLife's goal is committed to becoming the world's first cancer care complimentary digital therapeutic.
Recruitment Partners: Want to Join the Quality of Life Crusade?
CancerLife is teaming with several non profits and patient groups who want to come together help improve Quality of Life for all patients and participate in this pioneering study. All partners will have access to this data which will be shared with the industry to help improve care for all. We are calling this group of cancer organizations:
The Cancer "Quality of Life" Research Collaborative
If your non-profit is interested joining the crusade and participating, please contact CancerLife to learn more now.